Press Release: Santhera Announces Corporate -3-


Werte in diesem Artikel
Aktien

16.70 EUR -0.06 EUR -0.36 %

with the contemplated transaction described in this publication, may not

be publicly offered, directly or indirectly, in Switzerland within the

Werbung

meaning of the Swiss Financial Services Act ("FinSA"). Neither this

communication nor any other information material relating to the

securities referred to in this publication constitutes advertisement

within the meaning of the FinSA or a prospectus pursuant to the FinSA,

and no such prospectus has been or will be prepared for or in connection

with the transaction described in this publication.

Werbung

This publication does not constitute an offer to sell, or a solicitation

of an offer to purchase, any securities in the United States. The

securities of Santhera Pharmaceuticals Holding AG to which these

materials relate have not been and will not be registered under the

United States Securities Act of 1933, as amended (the "Securities Act"),

and may not be offered or sold in the United States absent registration

Werbung

or an applicable exemption from, or in a transaction not subject to, the

registration requirements of the Securities Act. There will not be a

public offering of securities in the United States.

This publication may contain certain forward-looking statements

concerning Santhera Pharmaceuticals Holding AG and its business. Such

statements involve certain risks, uncertainties and other factors which

could cause the actual results, financial condition, performance or

achievements of Santhera Pharmaceuticals Holding AG to be materially

different from those expressed or implied by such statements. Readers

should therefore not place undue reliance on these statements,

particularly not in connection with any contract or investment decision.

Santhera Pharmaceuticals Holding AG disclaims any obligation to update

these forward-looking statements.

# # #

Attachment

-- 2021 02 16_SannCorpUpdate_e_final

https://ml-eu.globenewswire.com/Resource/Download/cde220d6-79b2-4dd7-85e5-54b58bc5f76f

(END) Dow Jones Newswires

February 16, 2021 01:00 ET (06:00 GMT)

Aktuelle Santhera Pharmaceuticals Aktie News

Werbung

Santhera Pharmaceuticals Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Santhera Pharmaceuticals nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
28.02.11 Santhera Pharmaceuticals hold Vontobel Research
18.02.11 Santhera Pharmaceuticals hold Vontobel Research
08.02.11 Santhera Pharmaceuticals hold Vontobel Research
25.10.10 Santhera Pharmaceuticals hold Vontobel Research
14.10.10 Santhera Pharmaceuticals hold Vontobel Research

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.